TrialPath
Rheumatoid arthritis · Miami

Rheumatoid arthritis clinical trials in Miami

12 recruiting rheumatoid arthritis studies within range of Miami. Click any trial for full eligibility criteria and contact info.

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

NCT07404865 · Primary Sjogren's Disease
Recruiting

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease (UPSTREAM SjD)

PhasePhase 3
TypeInterventional
Age18 Years – 75 Years
WhereChandler, Arizona, United States + 48 more
SponsorVor Biopharma
▾Tap for details
Apply

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

Recruiting

The purpose of this study is to evaluate how well LY4213663 is tolerated and what side effects may occur in healthy participants and participants with rheumatoid arthritis (RA). The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last approximately 33 weeks excluding screening.

PhasePhase 1
TypeInterventional
Age18 Years – 75 Years
WhereAnniston, Alabama, United States + 9 more
SponsorEli Lilly and Company
▾Tap for details
Apply

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

NCT06991114 · Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc)
Recruiting

A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.

PhasePhase 2
TypeInterventional
Age18 Years
WhereTuscaloosa, Alabama, United States + 51 more
SponsorArtiva Biotherapeutics, Inc.
▾Tap for details
Apply

Phase 1b/2 Study of IV Sarilumab in Adult With RA

NCT07704580 · Rheumatoid Arthritis
Recruiting

This is a Phase 1/Phase 2 study with: * 5-arms design for Part A; * and a single arm for Part B. The purpose of this study is to measure PK parameters and safety with sarilumab intravenous (IV) with or without concomitant oral conventional synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) in male and female participants with moderately to severely active rheumatoid arthritis aged 18 years of age or older. Study details include: * The study duration will be up to 64 weeks. * The treatment duration will be up to 6 months for each study phase. * Part A has 10 visits, including a post-treatment end of study (EOS) follow-up visit. * For participants entering the open label extension to receive the approved 200 mg sarilumab every two weeks (Q2W) dose, there will be 3 additional study visits. * For the intra-study sarilumab 200 mg Q2W subcutaneous (SC) arm, participants will be evaluated over the course of 24 weeks plus post-treatment EOS follow-up visit following the schedule of activities (SoA) of Part A from Day -1 to Day 29 (total of 8 visits) and the SoA of Part B from Week 4 to Week 24 (total of 8 visits) and a post-treatment end of study (EOS) follow-up visit at Week 30 (Part B) for a total of 17 visits, including a post-treatment EOS follow-up visit. * Part B has 13 visits, including a post-treatment EOS follow-up visit.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WhereCentennial, Colorado, United States + 11 more
SponsorSanofi
▾Tap for details
Apply

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

Recruiting

The study is a randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.

PhasePhase 2
TypeInterventional
Age18 Years
WhereCutler Bay, Florida, United States + 10 more
SponsorSynAct Pharma Aps
▾Tap for details
Apply

Study of PTC844 in Participants With Active Rheumatoid Arthritis

NCT07779616 · Rheumatoid Arthritis
Recruiting

This study is designed to assess the safety, pharmacokinetics (PK), and biomarker effects of PTC844 compared to placebo in participants with active rheumatoid arthritis (RA).

PhasePhase 2
TypeInterventional
Age18 Years – 70 Years
WhereChandler, Arizona, United States + 25 more
SponsorPTC Therapeutics
▾Tap for details
Apply

Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry

NCT02418442 · Rheumatic Joint Disease
Recruiting

Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.

Phase—
TypeObservational
Age21 Years
WhereBirmingham, Alabama, United States + 81 more
SponsorDuke University
▾Tap for details
Apply

A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

Recruiting

This is a Phase 2 randomized, double-blind, placebo-controlled study with a total duration of 32 weeks from Screening to End-of-Study (EOS) Visit. Approximately 180 participants are planned to be enrolled. The number of participants can be extended to maximally 220 to account for dropouts during the study.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereGilbert, Arizona, United States + 33 more
SponsorElevara Medicines Limited
▾Tap for details

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Recruiting

Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. The purpose of this study is to assess the pharmacokinetics, pharmacodynamics and safety of ABBV-519 in adult participants with SLE or RA. This is a single ascending dose study in an estimated 30 adult participants with moderate SLE or RA. The total duration of the study will be approximately 425 days (60-day Screening Period, 1-day Treatment Period, and a 52 week Follow-up Period) at approximately 15 to 20 sites globally. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

PhasePhase 1
TypeInterventional
Age18 Years – 75 Years
WhereAnniston, Alabama, United States + 16 more
SponsorAbbVie
▾Tap for details
Apply

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

Recruiting

The main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part A) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C Part A). The trial will also assess the efficacy of SC blinatumomab in adult participants with active and refractory SLE with and without nephritis (Subprotocol B Part B and Subprotocol C Part B).

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereScottsdale, Arizona, United States + 57 more
SponsorAmgen
▾Tap for details
Apply

R-2487 in Patients With Rheumatoid Arthritis

NCT05961592 · Arthritis, Rheumatoid
Recruiting

The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Rheumatoid Arthritis. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Rheumatoid Arthritis. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.

PhasePhase 1
TypeInterventional
Age18 Years – 75 Years
WhereSan Diego, California, United States + 5 more
SponsorRise Therapeutics LLC
▾Tap for details
Apply

A Study of AZD0120 in Autoimmune Diseases

NCT07295847 · Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
Recruiting

This trial is a Phase 1b/2, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with systemic sclerosis (SSc), idiopathic inflammatory myopathies (IIM), or difficult-to-treat rheumatoid arthritis (D2T RA).

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years – 75 Years
WhereTucson, Arizona, United States + 26 more
SponsorAstraZeneca
▾Tap for details
Apply